Pulmonary fibrosis
MONDO:0002771Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).
Also known as: pulmonary interstitial fibrosis
188 clinical trials for this condition and its sub-types, 140 tagged with Pulmonary fibrosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pulmonary fibrosis
-
Tuberculous fibrosis of lung 3 trials
-
9 sub-types
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 7 0 trials
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8 0 trials
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9 0 trials
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1 0 trials
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 2 0 trials
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3 0 trials
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 4 0 trials
- Pulmonary fibrosis and/or bone marrow failure, telomere-related, 5 0 trials
- Pulmonary fibrosis and/or bone marrow failure, telomere-related, 6 0 trials
-
Diffuse pulmonary fibrosis 0 trials
-
Graphite pneumoconiosis 0 trials
-
Localized pulmonary fibrosis 0 trials
-
Postinflammatory pulmonary fibrosis 0 trials
-
Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
Disease control Not yet recruitingThis phase 3 trial tests an inhaled drug called treprostinil palmitil in adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time despite standard care. Participants inhale the drug or a placebo once daily for 52 weeks. Researchers measure whe…
Phase 3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Not yet recruitingThis study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a smartphone app replace hospital rehab for lung disease?
Disease control Not yet recruitingThis trial tests whether a digital rehabilitation programme called I-IMPACT can be a practical alternative to traditional centre-based pulmonary rehabilitation for adults with interstitial lung disease (ILD). The study will compare the two approaches, focusing on feasibility—such…
Sponsor: University Hospitals, Leicester • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug shows promise for lung scarring in Long-Term safety trial
Disease control Not yet recruitingThis study looks at the long-term safety of a drug called admilparant in people with pulmonary fibrosis (lung scarring). About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug is safe to use over time, …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can exercise and breathing training repair lungs damaged by TB?
Disease control Not yet recruitingThis study tests whether an 8-week supervised pulmonary rehabilitation program can improve breathing, exercise capacity, and quality of life in adults with persistent lung problems after completing tuberculosis treatment. Participants are randomly assigned to either the rehab pro…
Sponsor: Filantropia Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Smart cap aims to boost medication adherence in lung disease patients
Disease control Not yet recruitingThis study will test if a smart pill bottle cap, called FORTISKAP™, helps people with serious lung diseases like pulmonary fibrosis, sarcoidosis, and pulmonary hypertension take their oral medications more consistently. About 100 participants will either use the smart cap or rece…
Sponsor: Cosmos Rx, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to help lung fibrosis patients breathe easier
Disease control Not yet recruitingThis study tests whether adding nerandomilast to the standard drug mycophenolate is safe and tolerable for people with pulmonary fibrosis (lung scarring). About 120 adults with various types of lung fibrosis will take the combination for 4 months. The main goal is to see how many…
Phase 4 • Sponsor: University of British Columbia • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill aims to slow lung decline in scarring disease
Disease control Not yet recruitingThis Phase 3 trial tests whether HSK44459 tablets can slow the decline in lung function for adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. About 378 participants will take the drug or a placebo twice daily for 52 weeks. The main goa…
Phase 3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radioactive tracer aims to light up hidden lung scarring
Diagnosis Not yet recruitingResearchers at Mayo Clinic are testing an investigational radioactive tracer called 68Ga-FAPI-46 to see how it distributes in the lungs of people with interstitial lung disease. About 10 participants with a clinical diagnosis of ILD and lung abnormalities on a recent CT scan rece…
Phase 1 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Inhaled xenon gas could reveal hidden lung vessel disease without catheter
Diagnosis Not yet recruitingResearchers are testing a noninvasive MRI technique that uses inhaled hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis. The study includes about 51 participants, including healthy volunteers…
Phase 2 • Sponsor: Bastiaan Driehuys • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
New PET tracer aims to spot scarring in organs without a needle
Diagnosis Not yet recruitingThis study will test a new imaging agent called 68Ga-1A12, which is used in a PET scan to detect fibrosis (scarring) in organs like the lungs. The goal is to see if this scan can diagnose fibrosis earlier and more accurately than current methods, which often require invasive biop…
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Breathing exercises put to the test for scarred lungs
Symptom relief Not yet recruitingResearchers compare two breathing techniques added to standard medical care for people with stable pulmonary fibrosis. Forty adults with mild to moderate lung restriction join the study. One group receives a manual diaphragmatic release technique, where a therapist applies gentle…
Sponsor: Pharos University in Alexandria • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Virtual reality offers a new way to breathe easier for lung disease patients
Symptom relief Not yet recruitingThis study tests whether a virtual reality (VR) program that guides slow, controlled breathing and arm exercises can help people with interstitial lung disease (ILD) manage symptoms like breathlessness and fatigue. Participants will either use a VR headset or follow printed instr…
Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New study brings lung rehab to africa: can exercise programs help millions?
Symptom relief Not yet recruitingThis study tests whether a supervised exercise and education program (pulmonary rehabilitation) can help people with long-term lung diseases like COPD, asthma, and post-TB lung damage in Nigeria, South Africa, and Cameroon. Researchers will enroll 90 patients to see if the progra…
Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Hands-On therapy tested for lung disease: could osteopathic techniques ease breathing?
Symptom relief Not yet recruitingThis study tests whether adding osteopathic manipulative techniques (gentle hands-on bodywork) to standard chest physiotherapy can improve lung function and reduce shortness of breath in people with progressive pulmonary fibrosis. Fifty adults with advanced lung scarring will rec…
Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Pilates for lungs: new study tests gentle exercise for breathing problems
Symptom relief Not yet recruitingThis study tests whether a supervised Clinical Pilates program can improve physical function, breathing, and quality of life in 58 adults with interstitial lung disease (ILD). Participants are randomly assigned to either Pilates sessions plus standard care or standard care alone.…
Sponsor: Recep Tayyip Erdogan University • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New smart oxygen device aims to free lung patients from constant monitoring
Symptom relief Not yet recruitingThis study tests a lightweight, battery-powered device called MoblO2 that automatically adjusts oxygen flow to keep blood oxygen at a healthy level during exercise. It is designed for people with COPD or interstitial lung disease who need supplemental oxygen. Over two weeks, 48 p…
Sponsor: National Jewish Health • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Lung rehab may strengthen breathing muscles in scarred lung disease
Symptom relief Not yet recruitingInterstitial lung diseases cause lung scarring and stiffness, making it hard to breathe. This study will test whether an 8-week pulmonary rehabilitation program—including walking, cycling, and strength exercises—can improve diaphragm function, exercise ability, and quality of lif…
Sponsor: Hospital Civil de Guadalajara • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Spotting hidden blood clots in scarred lungs: a study hunts for clues
Knowledge-focused Not yet recruitingPeople with interstitial lung disease (ILD) can suddenly get much worse, but it is hard to tell if the cause is a lung flare-up or a blood clot in the lungs (pulmonary embolism). This observational study will follow 70 adults with ILD who come to the hospital with worsening breat…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
What makes someone stop a lung fibrosis drug? a study asks patients directly
Knowledge-focused Not yet recruitingThis study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Home devices may spot lung flare-ups before they become emergencies
Knowledge-focused Not yet recruitingThis study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
How safe is bronchoscopy for ILD patients? new study aims to find out
Knowledge-focused Not yet recruitingThis study will track 427 adults with interstitial lung disease (ILD) who need a bronchoscopy as part of their care. Researchers want to see how often complications happen within 30 days after the procedure. The goal is to better understand the risks so doctors can make safer cho…
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Simple blood test may predict lung damage in autoimmune diseases
Knowledge-focused Not yet recruitingThis study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis and systemic sclerosis, as well as healthy volunteers, and compare them with standard tests and lung functi…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lung wash test could unlock secrets of scarring lung diseases
Knowledge-focused Not yet recruitingThis study will use a procedure called bronchoalveolar lavage (BAL) to collect fluid from the lungs of 66 adults with suspected interstitial lung disease (ILD). The fluid will be analyzed to identify specific inflammatory cells, which may help doctors distinguish between differen…
Sponsor: Maha Ahmed Abd EL Gawad Mohammed Okasha • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC